physalaemin and Carcinoma--Small-Cell

physalaemin has been researched along with Carcinoma--Small-Cell* in 3 studies

Other Studies

3 other study(ies) available for physalaemin and Carcinoma--Small-Cell

ArticleYear
In vitro growth inhibition of human small cell lung cancer by physalaemin.
    Cancer research, 1987, May-01, Volume: 47, Issue:9

    Production and secretion of neuroendocrine peptides by small cell lung cancer (SCLC) has been detected in the past years. Most recently the role of bombesin as an autocrine/paracrine growth modifier has been demonstrated. We used the soft agarose clonogenic assay to evaluate the influence of other neuroendocrine peptides on the in vitro proliferation of SCLC cell lines. Neuroendocrine peptides tested were adrenocorticotropic hormone, arginine vasopressin, calcitonin, glucagon, kassinin, neurotensin, physalaemin, somatostatin, and substance P. Experiments were carried out in serum-free and serum-supplemented media with and without serum-free incubation periods. Our results indicated that the amphibian undecapeptide physalaemin inhibits the clonal and mass culture growth of SCLC cell lines at picomolar concentrations. All other neuroendocrine peptides failed to influence SCLC growth in the test systems used. These results suggest a growth regulating effect of physalaemin and a potential new form of neuroendocrine peptide therapy for SCLC.

    Topics: Adrenocorticotropic Hormone; Arginine Vasopressin; Calcitonin; Carcinoma, Small Cell; Cell Division; Glucagon; Humans; Kassinin; Kinins; Neurotensin; Oligopeptides; Physalaemin; Somatostatin; Substance P

1987
Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1985, Volume: 99

    Topics: Animals; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Kinins; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Physalaemin; Radioimmunoassay; Transplantation, Heterologous

1985
Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma.
    Science (New York, N.Y.), 1983, Jan-07, Volume: 219, Issue:4580

    Immunoreactivity to the amphibian peptide physalaemin was characterized from extracts of a human lung small-cell carcinoma by immunological, chemical, and pharmacological means. Tumor-related peptide cross-reacted with three antiserums to physalaemin to yield 1.1 to 1.6 nanomoles per gram of tissue. Physalaemin and tumor peptide had similar retention times on high-performance liquid chromatography after chemical and enzymic modifications that included pH changes, oxone oxidation, use of a hydrophilic ion-pairing reagent, and digestion with trypsin and pyroglutamate aminopeptidase. Both physalaemin and the tumor peptide produced a contractile response of isolated guinea pig ileum at threshold concentrations of approximately 100 to 150 picograms per milliliter. These data suggest that small-cell carcinoma of the lung contains a physalaemin-like peptide that has structural and biological homology to its amphibian counterpart.

    Topics: Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Cross Reactions; Humans; Immune Sera; Kinins; Lung Neoplasms; Oxidation-Reduction; Peptides; Physalaemin; Tachykinins

1983